EUVIMEDSkopri EUVIMED
Klinische Studie (Phase II)Multizentrische Studie

A Phase II Trial Using Grape Seed Extract for Prostate Cancer Patients With Nonmetastatic Prostate‐Specific Antigen Progression After Local Therapy

Paul Maroni, Tad A Manalo, Hannah Baker, Elizabeth R Kessler, Andrew Nicklawsky iD, Victor Trevisanut, Thomas W Flaig, Elaine T Lam, James C Moore, Dexiang Gao iD, Komal Raina iD, Rajesh Agarwal iD

Molecular Carcinogenesis · 2026-12 · 65 (12) · 1628-1637

DOI: 10.1002/mc.70183 ↗

At a glance

Klinische Studie (Phase II) in Molecular Carcinogenesis, published online on 2026-09-27. Written by Paul Maroni and 11 co-authors. Institution: Department of Surgery, Division of Urology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. Major MEDLINE topics: Grape Seed Extract, Prostate-Specific Antigen, Prostatic Neoplasms. 47 references. Funded by: NCI NIH HHS, Cancer League of Colorado, Politechnika Poznańska.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Prostate cancer (PCa) is a major cause of cancer‐related death among American men. While androgen deprivation therapy (ADT) is commonly used in the treatment of rising prostate‐specific antigen (PSA) levels after primary therapy, its adverse systemic side effects support exploring low‐impact treatment options during the observation period of nonmetastatic PSA‐only progression. Grape seed extract (GSE) is a nontoxic phytochemical that has shown anti‐PCa efficacy in preclinical studies. Herein, we report the results of a completed Phase II clinical trial (CT.gov‐NCT03087903) which investigated the effect of GSE in patients with PSA‐only recurrence after maximum local therapy for PCa. Study endpoints included PSA response (defined as a ≥ 30% increase in model‐estimated PSA‐DT) and change in PSA velocity. Forty‐one patients were given 150 mg of GSE orally twice daily (Leucoselect‐Phytosome formulation with increased bioavailability) for 12 months or until PSA‐DT ≤ 3 months. Mixed‐effects spline modeling of longitudinal PSA demonstrated a modest increase in PSA‐DT following treatment initiation. Most patients experienced some degree of increase in model‐estimated PSA‐DT, with 37% of those patients meeting the primary endpoint of ≥ 30% increase in PSA‐DT. GSE demonstrated a favorable safety profile. Although further validation is warranted, the observed changes in PSA‐DT indicate that GSE may contribute to delaying PCa progression. The therapeutic effect appeared to be more pronounced among patients with higher baseline PSA and testosterone levels, suggesting that these factors may influence responsiveness to treatment. These promising findings support further investigation to identify patient populations most likely to benefit from GSE intervention. Trial Registration: ClinicalTrials.gov site (CT.gov‐NCT03087903).

Subjects

MeSH terms (MEDLINE)

Grape Seed ExtractProstate-Specific AntigenProstatic NeoplasmsAgedHumansMaleMiddle AgedDisease Progression

Author keywords

biochemical recurrencegrape seed extractnonmetastaticprostate cancerprostate‐specific antigen

Substances

Grape Seed ExtractProstate-Specific Antigen

Authors and institutions

  • Department of Surgery, Division of Urology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Department of Internal Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • UCHealth Cancer Care and Hematology Clinic - Harmony Campus, Fort Collins, Colorado, USA.
  • Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Department of Pharmaceutical Sciences, South Dakota State University, Brookings, South Dakota, USA.

ORCID profiles: Andrew Nicklawsky, Dexiang Gao, Komal Raina, Rajesh Agarwal

Funding

  • NCI NIH HHS
  • Cancer League of Colorado
  • Politechnika Poznańska

Cite

APA

Maroni, P., Manalo, T. A., Baker, H., Kessler, E. R., Nicklawsky, A., Trevisanut, V., Flaig, T. W., Lam, E. T., Moore, J. C., Gao, D., Raina, K., & Agarwal, R. (2026). A Phase II Trial Using Grape Seed Extract for Prostate Cancer Patients With Nonmetastatic Prostate‐Specific Antigen Progression After Local Therapy. Molecular Carcinogenesis, 65(12), 1628-1637. https://doi.org/10.1002/mc.70183

Vancouver

Maroni P, Manalo TA, Baker H, Kessler ER, Nicklawsky A, Trevisanut V, et al. A Phase II Trial Using Grape Seed Extract for Prostate Cancer Patients With Nonmetastatic Prostate‐Specific Antigen Progression After Local Therapy. Molecular Carcinogenesis. 2026;65(12):1628-1637. doi:10.1002/mc.70183

BibTeX
@article{Maroni2026,
  author = {Maroni, Paul and Manalo, Tad A and Baker, Hannah and Kessler, Elizabeth R and Nicklawsky, Andrew and Trevisanut, Victor and Flaig, Thomas W and Lam, Elaine T and Moore, James C and Gao, Dexiang and Raina, Komal and Agarwal, Rajesh},
  title = {A Phase II Trial Using Grape Seed Extract for Prostate Cancer Patients With Nonmetastatic Prostate‐Specific Antigen Progression After Local Therapy},
  journal = {Molecular Carcinogenesis},
  year = {2026},
  volume = {65},
  number = {12},
  pages = {1628--1637},
  doi = {10.1002/mc.70183}
}
Start for free →